Lipocine Inc (LPCN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lipocine Inc (LPCN) has a cash flow conversion efficiency ratio of -0.211x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.99 Million) by net assets ($14.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lipocine Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Lipocine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LPCN total debt and obligations for a breakdown of total debt and financial obligations.
Lipocine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipocine Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thunderful Group AB
ST:THUNDR
|
-0.023x |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
-0.022x |
|
Vesuvius PLC
LSE:VSVS
|
0.022x |
|
AUGA GROUP AB EO 029
F:W9Z
|
N/A |
|
Breedon Group PLC
LSE:BREE
|
0.010x |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
0.322x |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
-0.862x |
|
Golden Land Bhd
KLSE:7382
|
-0.063x |
Annual Cash Flow Conversion Efficiency for Lipocine Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Lipocine Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see LPCN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $21.00 Million | $-1.22 Million | -0.058x | +90.02% |
| 2023-12-31 | $20.37 Million | $-11.87 Million | -0.583x | -73.44% |
| 2022-12-31 | $35.63 Million | $-11.97 Million | -0.336x | -246.97% |
| 2021-12-31 | $45.57 Million | $-4.41 Million | -0.097x | +90.30% |
| 2020-12-31 | $15.34 Million | $-15.30 Million | -0.997x | +46.24% |
| 2019-12-31 | $6.29 Million | $-11.67 Million | -1.855x | -44.91% |
| 2018-12-31 | $9.43 Million | $-12.08 Million | -1.280x | -45.50% |
| 2017-12-31 | $18.98 Million | $-16.70 Million | -0.880x | -25.23% |
| 2016-12-31 | $26.02 Million | $-18.28 Million | -0.703x | -92.12% |
| 2015-12-31 | $41.99 Million | $-15.36 Million | -0.366x | +44.28% |
| 2014-12-31 | $26.36 Million | $-17.30 Million | -0.656x | -242.61% |
| 2013-12-31 | $44.82 Million | $-8.59 Million | -0.192x | -103.45% |
| 2012-12-31 | $-11.32K | $-62.87K | 5.555x | +1991.53% |
| 2011-12-31 | $24.84K | $-7.29K | -0.294x | -- |
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation lon… Read more